Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer
Keiko Ohgino(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Shinnosuke Ikemura(Keio University), Yuichiro Hayashi(Keio University), Aoi Kuroda(Keio University), Hideki Terai(Kitasato Institute Hospital), Kota Ishioka(Keio University), Daisuke Arai(Keio University), Katsuhiko Naoki(Broad Institute), Takashi Sato(Kitasato University), Hiroyuki Yasuda(Keio University), Kenzo Soejima(Keio University), Junko Hamamoto(Keio University), Tetsuo Tani(Keio University)
Cited by 49
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101